Legacy Company Profile
What is the competitive landscape for LEGACY
LEGACY has twenty-four approved drugs.
There are twenty-nine US patents protecting LEGACY drugs.
Summary for Legacy
| US Patents: | 29 |
| Tradenames: | 17 |
| Ingredients: | 15 |
| NDAs: | 24 |
Drugs and US Patents for Legacy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legacy | ESBRIET | pirfenidone | TABLET;ORAL | 208780-003 | Jan 11, 2017 | AB | RX | Yes | Yes | 7,767,700 | ⤷ Start Trial | ⤷ Start Trial | |||
| Legacy | ESBRIET | pirfenidone | TABLET;ORAL | 208780-001 | Jan 11, 2017 | AB | RX | Yes | No | 8,013,002 | ⤷ Start Trial | ⤷ Start Trial | |||
| Legacy | ZANAFLEX | tizanidine hydrochloride | TABLET;ORAL | 020397-002 | Feb 4, 2000 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| Legacy | IMURAN | azathioprine | TABLET;ORAL | 016324-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Legacy
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Legacy | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | 4,414,209 | ⤷ Start Trial |
| Legacy | LOTRONEX | alosetron hydrochloride | TABLET;ORAL | 021107-001 | Feb 9, 2000 | 6,284,770 | ⤷ Start Trial |
| Legacy | BRISDELLE | paroxetine mesylate | CAPSULE;ORAL | 204516-001 | Jun 28, 2013 | 5,874,447 | ⤷ Start Trial |
| Legacy | RIDAURA | auranofin | CAPSULE;ORAL | 018689-001 | May 24, 1985 | 4,364,923 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for LEGACY drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Capsules | 7.5 mg | ➤ Subscribe | 2014-04-07 |
| ➤ Subscribe | Capsules | 2 mg, 4 mg and 6 mg | ➤ Subscribe | 2007-08-10 |
| ➤ Subscribe | Tablets | 0.5 mg and 1 mg | ➤ Subscribe | 2010-12-02 |
| ➤ Subscribe | Tablets | 267 mg, 534 mg and 801 mg | ➤ Subscribe | 2018-10-15 |
| ➤ Subscribe | For Injection | 500 mg/vial | ➤ Subscribe | 2004-04-16 |
International Patents for Legacy Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Hong Kong | 1176002 | ⤷ Start Trial |
| Hong Kong | 1153647 | ⤷ Start Trial |
| European Patent Office | 2068881 | ⤷ Start Trial |
| Australia | 2010212490 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Legacy Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0809498 | 10C0038 | France | ⤷ Start Trial | PRODUCT NAME: ACYCLOVIR ET HYDROCORTISONE; NAT. REGISTRATION NO/DATE: NL 36 826 20100420; FIRST REGISTRATION: SK - 2108/08467-R 20091026 |
| 0809498 | SPC/GB10/012 | United Kingdom | ⤷ Start Trial | PRODUCT NAME: A COMBINATION OF ACYCLOVIR AND HYDROCORTISONE; REGISTERED: UK PL18191/0001-0001 20091112 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
